Tagomics in genomics initiative with Agilent Technologies

The initiative offers select customers the opportunity to access Tagomics’ and Agilent Technologies’ combined innovative offerings through an exclusive technology access programme hosted out of Tagomics’ service lab at Granta Park, Cambridge.

Tagomics has developed a novel multiomics platform, InterlaceTM, that unlocks disease-associated DNA biomarkers from a range of biological sources.

Its technology leverages what it regards as a unique approach to epigenetic profiling which specifically enriches unmethylated DNA for analysis without modifying the underlying DNA sequence.

The Interlace platform seamlessly integrates whole genome sequencing or targeted sequencing and, combined with its advanced bioinformatics and machine learning software, enables the analysis of epigenetic, genetic and fragmentomic features in a single, cost-effective, low-input, and automatable workflow.

Agilent Technologies provides comprehensive solutions for targeted genomic profiling. The SureSelect Library Preparation and Target Enrichment System, combined with the SureSelect Cancer panels, enables efficient detection of a wide array of somatic variants in solid tumours.

These include single nucleotide variants, copy number variants, insertions/deletions, translocations, gene fusions and the immuno-oncology biomarkers TMB (tumour mutational burden) and MSI (microsatellite instability).

Tagomics has seamlessly integrated Agilent’s SureSelect XT HS2 Library Preparation and Target Enrichment System into its multiomic workflow. This combination enables comprehensive genomic and epigenomic insights, all within a single, unified workflow.

To showcase the potential of this combined approach, Tagomics has signed a co-marketing agreement with Agilent and launched the technology access programme.

This allows select customers to experience the enhanced capabilities of the combined platform ahead of the broader market. Tagomics says customers will benefit from more comprehensive insights into the mechanisms driving disease, opening the door to novel diagnostic and therapeutic strategies.

Dr Jack Kennefick, CEO and co-founder of Tagomics said: “We’re pleased to be working with Agilent Technologies to bring select customers the combined capabilities of our respective platforms, unified in Tagomics’ Interlace multiomic workflow.

“Through this collaboration, we look forward to empowering customers with deeper biological insights and accelerating the development of innovative diagnostic and therapeutic solutions.”

Ronda Allen, general manager of Genomics at Agilent Technologies added: “Through our agreement, our customers will have access to Tagomics’ Interlace platform and advanced bioinformatics software, enabling simultaneous genetic and genome-wide epigenomic profiling.

“Incorporation of our SureSelect Library Preparation and Target Enrichment System into Tagomics’ workflow complements our established capabilities in genomic profiling, furthering our mission to bring great science to life.”

Tagomics was launched in 2021 as a spin out from The University of Birmingham to build upon research led by Dr Robert Neely, the company’s Chief Scientific Officer. It aims to discover novel disease markers and apply them to advance diagnostic and drug development. To support this mission, Tagomics has raised over £8 million from investors from Cambridge and elsewhere including Calculus Capital, Illumina Ventures, IQ Capital, Agilent Ventures, Mercia Ventures, Meltwind, OMX Ventures, and Start Codon.